Initial sequencing and analysis of the human genome

Eric S. Lander, Lauren Linton, Bruce W. Birren, +120

Nature

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo, +14

New England Journal of Medicine

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke, +19

Nature Communications

Tumor BiologyTumor ImmunologyCancer ImmunosurveillanceCheckpoint InhibitorsGenitourinary Cancer +12

Why animals have different muscle fibre types

Lawrence C. Rome, Roel Funke, R. McNeill Alexander, +4

Nature

Animal PhysiologyMuscle FunctionSkeletal MusclePhysiologyBiomechanics +1

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

Sylvia Adams, Jennifer R. Diamond, Erika Hamilton, +9

JAMA Oncology

Non-viral precision T cell receptor replacement for personalized cell therapy

Susan P. Foy, Kyle Jacoby, Daniela A. Bota, +51

Nature

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Marcin Kowanetz, Wei Zou, Scott Gettinger, +27

Proceedings of the National Academy of Sciences

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

David R. Spigel, Jamie E. Chaft, Scott Gettinger, +11

Journal of Thoracic Oncology

Biomarker (Medicine)Therapeutic Drug MonitoringBiomarker AnalysisMedicinePd-l1–selected Patients +5

The Influence of Temperature on Muscle Velocity and Sustained Performance in Swimming Carp

Lawrence C. Rome, Roel Funke, R. McNeill Alexander

Journal of Experimental Biology

EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

Torsten Trowe, Sotiria Boukouvala, Keith Calkins, +13

Clinical Cancer Research